This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Vimizim

BioMarin Pharmaceutical Inc.

Drug Names(s): GALNS, recombinant human N-acetylgalactosamine-6-sulfate sulfatase (rhGALNS), BMN 110, elosulfase alfa

Description: BMN 110 is an enzyme replacement of N-acetylgalactosamine-6-sulfate sulfatase (GALNS).

MPS IVA, also known as Morquio A Syndrome, is a disorder characterized by deficient activity of GALNS causing excessive lysosomal storage of keratan sulfate (KS). This excessive storage causes a systemic skeletal dysplasia, short stature, and joint abnormalities, which limit mobility and endurance.


Vimizim News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug